Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation
Brief Summary: The purpose of this study is to provide information on the risks and benefits of routine blood pressure lowering (regardless of blood pressure level), and intensive lowering of blood glucose levels, in patients with Type 2 diabetes at high risk of cardiovascular events. The major outcomes of the study will be cardiovascular events (heart attack, stroke or dying as a result of cardiovascular disease), as well as new or worsening diabetic eye and kidney disease.


Options:
A: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
B: Arm Label: Anti-VEGF+Deferred PRP; Type: EXPERIMENTAL; Interventions: Drug: 0.5-mg Ranibizumab, Other: Deferred panretinal photocoagulation | Arm Label: Prompt PRP; Type: ACTIVE_COMPARATOR; Interventions: Other: Prompt Panretinal Photocoagulation | Intervention Type: OTHER; Name: Prompt Panretinal Photocoagulation; Assigned to Arm(s): Prompt PRP | Intervention Type: DRUG; Name: 0.5-mg Ranibizumab; Assigned to Arm(s): Anti-VEGF+Deferred PRP | Intervention Type: OTHER; Name: Deferred panretinal photocoagulation; Assigned to Arm(s): Anti-VEGF+Deferred PRP
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Arm Label: Intensive glycemia control; Type: EXPERIMENTAL; Interventions: Drug: Hypoglycemic Agents | Arm Label: Standard glycemia control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard glycemia control | Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP treatment | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Arm Label: Fibrate; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate, Drug: Simvastatin | Arm Label: Fibrate Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Hypoglycemic Agents; Assigned to Arm(s): Intensive glycemia control | Intervention Type: DRUG; Name: Standard glycemia control; Assigned to Arm(s): Standard glycemia control | Intervention Type: DRUG; Name: Intensive BP treatment; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): Fibrate | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Fibrate, Fibrate Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fibrate Placebo

Answer: C